ArticleBMJ open2022

Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.

Satoshi Okumura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.